Analyst Insights: Edwards Lifesciences, MAKO Surgical, Jabil Circuit, Liquidity Services June 14th

Edwards Lifesciences Corp. (NYSE:EW): Deutsche Bank believes the favorable FDA panel vote last night for Edwards Lifesciences’ SAPIEN and FDA approval was already priced into shares. The firm raised its price target for Edwards Lifesciences to $80 from $75 but maintains a Hold rating on the stock. Citigroup raised its price target for Edwards Lifesciences after the FDA circulatory system devices advisory panel voted in favor of the company’s SAPIEN transcatheter aortic heart valve for use in high risk patients. The firm maintains a Buy rating on the stock.

MAKO Surgical Corp. (NASDAQ:MAKO): William Blair believes the 5% pullback yesterday in shares of MAKO Surgical was not based on anything management said during the firm’s conference. William Blair notes MAKO management reiterated its full]year guidance, which calls for system placements between 52]58 and procedure volumes between 11,000 and 13,000. The firm views current share levels as a compelling entry point and keeps an Outperform rating on the stock.

Jabil Circuit Inc. (NYSE:JBL): Citigroup lowered its estimates for Jabil Circuit below the company’s guidance and consensus citing disappointing outlooks from Jabil’s major customers Research in Motion, Cisco, Hewlett-Packard and NetApp. Citi dropped its price target for shares to $21 from $30 and keeps a Hold rating on Jabil ahead of the company’s Q3 results on June 19.

Liquidity Services, Inc. (NASDAQ:LQDT): Benchmark Co. attributes the recent 10% pullback in shares of Liquidity Services to profit taking and views current levels as providing an attractive entry point. The firm expects the company’s results will continue to surprise to the upside and keeps a Buy rating on shares with a $73 price target.

Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.